Resolute zotarolimus‐eluting stent in ST‐elevation myocardial infarction (resolute‐STEMI): A prespecified prospective register from the DAPT‐STEMI trial
- Postma, Warner Isala Hartcentrum, Zwolle, the Netherlands
- Fabris, Enrico Isala Hartcentrum, Zwolle, the Netherlands - Cardiovascular Department, University of Trieste, Trieste, Italy
- Ent, Martin Van der Maasstad Ziekenhuis, Rotterdam, the Netherlands
- Hermanides, Rik Isala Hartcentrum, Zwolle, the Netherlands
- Buszman, Pawel American Heart of Poland, Uströn, Poland - Medical University of Silesia, Katowice, Poland
- Birgelen, Clemens Von Thoraxcenter, Erasmus Medisch Centrum, Rotterdam, the Netherlands - Medisch Spectrum Twente, Enschede, the Netherlands
- Cook, Stéphane Department of Cardiology, University of Fribourg and Hospital, Fribourg, Switzerland
- Wedel, Hans Sahlgrenska Academy, University of Gothenburg and Nordic School of Public Health, Gothenburg, Sweden
- Luca, Giuseppe De Department of Cardiology, Eastern Piedmont University, Novara, Italy
- Delewi, Ronak Heart Centre, Academic Medical Centre, University Medical Center Amsterdam, the Netherlands
- Zijlstra, Felix Thoraxcenter, Erasmus Medisch Centrum, Rotterdam, the Netherlands
- Kedhi, Elvin Isala Hartcentrum, Zwolle, the Netherlands
-
03.07.2019
Published in:
- Catheterization and Cardiovascular Interventions. - 2019, p. ccd.28376
English
To evaluate the safety and efficacy outcomes after primary percutaneous coronary intervention (pPCI) with second‐generation Resolute™ zotarolimus‐eluting stent (R‐ ZES) in patients enrolled in the DAPT‐STEMI Trial (NCT01459627).Background: R‐ ZES is one of the most used drug eluting stents worldwide. To date, the safety and efficacy data of this stent in setting of STEMI is limited.Methods: The Resolute‐STEMI is a prespecified prospective register that reports the safety and efficacy of R‐ZES in setting of ST‐Elevation Myocardial Infarction (STEMI) at 6 months for the following endpoints: a composite endpoint of all‐cause mortality, any myocardial infarction (MI), any (unscheduled) revascularization, stroke and TIMI major bleeding, as well as target lesion failure and stent thrombosis (ST).Results: From a total of 1,100 STEMI patients enrolled in the trial, 998 received a R‐ZES. At 6 months the PE occurred in 42 (4.2%) patients. All‐cause death, MI, revascularization, stroke and TIMI major bleeding was respectively 8 (0.8%), 9 (0.8%), 34 (3.4%), 2 (0.2%), and 4 (0.4%). The rate of target lesion revascularizations involving the culprit lesion was 1.1%. Target lesion failure was 1.5%. The rate of definite ST was 0.5%. The rate of both definite or probable ST was 0.7%.Conclusions: The present analysis is the largest to date reporting short‐ term and mid‐term clinical outcomes with the R‐ZES stent in setting of STEMI. At 30 days and 6‐months R‐ZES has an outstanding safety and efficacy even in this high‐ risk category of patients.
- Faculty
- Faculté des sciences et de médecine
- Department
- Médecine 3ème année
- Language
-
- English
- Classification
- Medicine
- License
- License undefined
- Identifiers
-
- RERO DOC 326985
- DOI 10.1002/ccd.28376
- Persistent URL
- https://folia.unifr.ch/unifr/documents/308177
Statistics
Document views: 67
File downloads:
- coo_rze.pdf: 96